Strong start to 2022 continues as Creo completes multi-national training course

Creo Medical Group plc has continued its strong start to 2022 having held its first expanded international Speedboat® training course at the CREBA facility in Lleida, Spain.

Cementing Creo’s international credentials, 13 doctors from as far afield as Israel, Chile and South Africa joined some of the multi-modal instruments’ most prominent users worldwide for two-day’s intensive training, which forms part of Creo Medical’s heralded Professional Clinical Education Programme.  The programme is designed to dramatically reduce the training time for potential users before they undergo a period of mentoring and case reviews to ensure optimal use of Creo’s flagship Speedboat® Inject device.

Nisha Patel, a Consultant at Imperial College London, who attended the training course said:

My experience of this professional education programme is that it is really excellent, it’s nothing like I have ever experienced before and I have been on several ESD courses. I think particularly from this it is not only about the lesion recognition, the complications and the case selection; it is also the mentoring aspect you get after this course, which is again very difficult to get on other courses with similar sort of mentoring so this is really key

Craig Gulliford, Chief Executive Officer of Creo, commented:

It is fantastic to see the increasing demand for our Speedboat® Inject product and the positive impact it’s having on patients worldwide – it is now a truly global product and has been used by gastroenterologists and surgeons in every continent bar Antarctica!

“We know that what we have, both in terms of our CROMA advanced energy platform, and the devices that are powered by our Kamaptive Technology, has the real potential to be at the forefront of a paradigm shift away from traditional surgical methods and towards surgical endoscopy.

“There is no question that Covid has restricted international training for the best part of two years, but what is already clear from the early part of 2022 is that we are seeing a long list of clinicians very excited by Creo’s technology, our products, our clinical education programme and the possible improvement to outcomes for their patients and healthcare providers.

Posted 03/31/22

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read